A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...